Addition of Heparin to Taurolock-TM CLS in HD Patients With TCC Dose it Improve Catheter Patency Problems ?
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00749619|
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : September 9, 2008
|Condition or disease||Intervention/treatment||Phase|
|End Stage Renal Disease Hemodialysis||Other: Catheter Lock Solution Taurolidine and Citrate Other: Catheter Lock Solution :Taurolidine and Citrate and Heparin Other: Catheter Lock Solution : Heparin||Phase 3|
Bacteremia and thrombosis are the major complications of TCC used for hemodialysis.Instilation of CLS containing antibiotic-anticoagulant solution in the end of each dialysis session till the next dialysis ,can prevent Catheter related bacteremia (CRB).In previous study in our department, Taurolock-TM decreased the rate of CRB but increased the incidence of catheter malfunction.
The aim of the study is to investigate the influence of of Heparin addition to CLS-Taurolock- TM ( Taurolidine &citrate 4%) in prevention of catheter patency problems in HD patients with TCC, in addition to CRB prevention.
Methods : Patients with newly inserted TCC for HD enrolled and randomized to receive one of three CLS types : group 1- Taurolock-TM, Group 2 - Taurolock-TM and Heparin , Group 3- Heparin .Patients were followed for 6 monthes.
The objective of the study is to investigate the effect of Taurolock TM with heparin on the rate of CRB and vascular patency.
|Study Type :||Interventional (Clinical Trial)|
|Study Start Date :||May 2007|
|Actual Primary Completion Date :||August 2008|
|Actual Study Completion Date :||August 2008|
|Experimental: A||Other: Catheter Lock Solution Taurolidine and Citrate|
|Experimental: B||Other: Catheter Lock Solution :Taurolidine and Citrate and Heparin|
|No Intervention: C||Other: Catheter Lock Solution : Heparin|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00749619
|Western Galilee Hospital|